• Which Patients Are at Greatest Risk From Mushroom Poisoning?

Which Patients Are at Greatest Risk From Mushroom Poisoning?

Almost 20% of patients with liver damage from mushroom (Amanita) poisoning and peak levels of total bilirubin greater than 2 mg/dL require liver transplantation or die, researchers report in the May issue of Clinical Gastroenterology and Hepatology. The authors show that peak level of aspartate aminotransferase (AST) below 4000 IU/L identifies

Read more
  • What are the Effects of Prednisolone in Patients With Severe Alcoholic Liver Disease?

What are the Effects of Prednisolone in Patients With Severe Alcoholic Liver Disease?

Infections are frequent in patients with severe alcoholic liver disease, but are only independently associated with mortality when patients receive prednisolone, researchers report in the April issue of Gastroenterology. This could offset prednisolone’s therapeutic benefit. This study’s senior author, Mark Thursz, discusses the findings in a video abstract. As with

Read more
  • Can Disruption of the Intestinal Epithelial Barrier Contribute to Steatohepatitis?

Can Disruption of the Intestinal Epithelial Barrier Contribute to Steatohepatitis?

Mice with defects in intestinal epithelial permeability develop more severe steatohepatitis when placed on a diet high in saturated fat, fructose, and cholesterol (HFCD) than control mice, and colon tissues from patients with non-alcoholic fatty liver disease (NAFLD) have similar defects in intestinal epithelial permeability, researchers report in the October

Read more
  • Medicaid Denies Almost 50% of Prescriptions for Hepatitis C Drugs in 4 States

Medicaid Denies Almost 50% of Prescriptions for Hepatitis C Drugs in 4 States

Medicaid programs in Delaware, Maryland, New Jersey, and Pennsylvania denied nearly half of all claims in the past year for direct-acting antiviral (DAA) hepatitis C drugs, according to an analysis of pharmacy data presented at the American Association for the Study of Liver Diseases 2015 Liver Meeting. The finding confirms

Read more
  • Improving Outcomes of Patients With Fibrosing Cholestatic Hepatitis C

Improving Outcomes of Patients With Fibrosing Cholestatic Hepatitis C

Sofosbuvir-based regimens, with or without daclatasvir, greatly improve the clinical status of patients who develop fibrosing cholestatis hepatitis (FCH) after liver transplantation for hepatitis C virus (HCV) infection, and most of the patients achieve a sustained virologic response (SVR), researchers report in the November issue of Clinical Gastroenterology and Hepatology. These results

Read more
  • Special Issue: Managing Patients With Liver Disease

Special Issue: Managing Patients With Liver Disease

A special issue of Clinical Gastroenterology and Hepatology is dedicated to the clinical management of hepatic disorders, including nonalcoholic fatty liver disease (NAFLD), viral hepatitis, autoimmune hepatitis, and primary sclerosing cholangitis (PSC). The issue comprises 14 review articles that aim to present clinicians with evidence-based guidance and expert opinions on management of patients with liver

Read more
  • Poor Adherence to Guidelines in Many Cases of Isoniazid-induced Liver Injury

Poor Adherence to Guidelines in Many Cases of Isoniazid-induced Liver Injury

Isoniazid is used to treat tuberculosis but is also a leading cause of liver injury. However, it is not clear how many cases of isoniazid-associated liver injury are reported or how many clinicians and patients adhere to American Thoracic Society (ATS) guidelines. In the September issue of Clinical Gastroenterology and Hepatology,

Read more
  • Public Health Officials Call for Wider Access to HCV Drugs

Public Health Officials Call for Wider Access to HCV Drugs

Experts from the Public Health Service and President Obama’s Advisory Council on HIV/AIDS are calling on federal and state Medicaid officials to widen access to prescription drugs that could cure tens of thousands of people with hepatitis C virus (HCV) infection. They say restrictions on the drugs imposed by many

Read more
  • What Causes Different Types of Fatty Liver Disease?

What Causes Different Types of Fatty Liver Disease?

Hepatic steatosis and steatohepatitis are increasing in prevalence, and can progress to histologically identical, more severe liver disease. They are associated with 3 main factors: alcohol, obesity or metabolic syndrome, and exposure to toxins. Researchers review the similarities, differences, and pathogenic mechanisms of alcohol-associated steatohepatitis (ASH), nonalcoholic steatohepatitis (NASH), and toxicant-associated fatty liver

Read more
  • An Effective and Long-lasting Hepatitis E Vaccine

An Effective and Long-lasting Hepatitis E Vaccine

A long-term study of a hepatitis E virus (HEV) vaccine showed that it is 86.8% effective and that immunity can last for up to 4.5 years. In a blinded, placebo-controlled, phase 3 trial, Jun Zhang et al randomly assigned 112,604 healthy adults in Dongtai (in the Jiangsu province of China)

Read more